HAEMATOLOGICAL COMPLICATIONS OF ANTI-TUBERCULOSIS CHEMOTHERAPY
Abstract
Haematological abnormalities are rare, but potentially fatal complications of anti-tuberculosis chemotherapy. Cytopenias are considered the most clinically significant type of adverse haematotoxic reactions. Anti-tuberculosis drugs may reduce a pool of any blood cells by either myelosuppression (inhibition of it’s generation in the bone marrow) or it’s accelerated destruction in the bloodstream. The review contains data about main pathways and clinical features of anemia, isolated leucopenia, trombocytopenia and pancytopenia; anti-tuberculosis drugs responded to different types of these disorders are listed. The modern experience for diagnostics and correction of haematotoxic reactions is summarized taking into account the realities of phthisiatrician practice.
About the Author
D. A. Ivanova
ГКУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
References
1. Аксенова В.А., Апт А.С., Баринов В.С. и др. Национальное руководство по фтизиатрии / под ред. М.И. Перельмана. – М.: Гэотар-Медиа, 2010. – 512 с.
2. Астахова А.В., Лепахин В.К. Лекарства: неблагоприятные побочные эффекты и контроль безопасности. 2-е изд. – М.: ЭКСМО, 2008. – 265 с.
3. Волкова С.А., Боровков Н.Н.. Основы клинической гематологии: учебное пособие. – Н. Новгород: Издательство НГМА, 2013. – 400 с.
4. Гематология: руководство для врачей / под ред. Н.Н. Мамаева, С.И. Рябова. – СПб.: СпецЛит, 2008. – 543 с.
5. Гусева С. А., Вознюк В. П., Дубкова А. Г. Анемии: вопросы диагностики и лечения / под ред. С.А. Гусевой. – Киев: Фахивец, 1999. – 150 с.
6. Дворецкий Л.И. Алгоритмы диагностики и лечения анемий //Российский медицинский журнал. – 2003. – № 8. – С. 427-433.
7. Дроздов А.А., Дроздова М.В. Заболевания крови. Полный справочник. – М.: Эксмо, 2008. – 608 с.
8. Зарецкий М.М., Черникова Н.М. Агранулоцитоз: от диагностики к выбору лечебной тактики // Therapia. – 2011. – № 1. – С. 27-29.
9. Иванова Д.А., Борисов С.Е., Рыжов А.М., Иванушкина Т.Н. Частота и риск развития тяжёлых нежелательных реакций при лечении впервые выявленных больных туберкулёзом // Туберкулез и болезни легких. – 2012. – № 12. – С. 15-22.
10. Каминская Г.О., Абдуллаев Р.Ю., Батурова Г.А., Комиссарова О.Г. Специфические особенности обмена железа при лечении больных туберкулезом легких // Проблемы туберкулеза и болезней легких. – 2009. – № 7. – С. 46-55
11. Ливчане Э. Лекарственная непереносимость, методы ее диагностики и коррекции при лечении больных туберкулезом легких противотуберкулезными препаратами резервного ряда: Автореф. дисс. … канд. мед. наук. – М., 2003. – 24 с.
12. Мишин В.Ю. Медикаментозные осложнения комбинированной химиотерапии туберкулеза легких. – М.: ООО «Медицинское информационное агентство», 2007. – 248 с.
13. Пивник А.В., Бойко Д.В., Тонкоглаз В.Н. Гаптеновый агранулоцитоз: лечение гемопоэтическими ростовыми факторами // Клиническая медицина. – 2006. – Т. 84. – № 3. – С. 55-59.
14. Руководство по гематологии. Т. 2. / под ред. А.И. Воробьева. – М.: Ньюдиамед, 2003. – 292 с.
15. Руководство по гематологии. Т. 3. / под ред. А.И. Воробьева. – М.: Ньюдиамед, 2005. – 416 с.
16. Финогенова Н.А. Анемии у детей (диагностика, дифференциальная диагностика, лечение). – М.: Макс-Пресс, 2004. – 109 с.
17. Abed M., Towhid S. T., Shaik N., Lang F. Stimulation of suicidal death of erythrocytes by rifampicin // Toxicology. – 2012. – Vol. 302. – N. 2-3. – P. 123-128.
18. Agrawal A., Gutch M., Jain N., Singh A. Do not miss rifampicin-induced thrombocytopenic purpura // BMJ Case Rep. – 2012. – URL: http://casereports.bmj.com/content/2012/bcr.12.2011.5282. – Accessed 02.07.14.
19. Agarwal A.K., Chugh I. M., Punjabi C. et al. Asymptomatic aplastic anaemia in a patient receiving anti-tuberculosis treatment // Ind. J. Tub. – 2001. – Vol. 48. – P. 97-100.
20. Apseloff G. Severe neutropenia among healthy volunteers given rifabutin in clinical trials // Clin. Pharmacol. Ther. – 2003. – Vol.74. – N. 6. – P. 591-593.
21. Attassi K., Hershberger E., Alam R., Zervos M.J. Thrombocytopenia associated with linezolid therapy // Clin Infect Dis. – 2002. – N. 34. – P. 695–698.
22. Bansal R., Sharma P.K., Sharma A. A case of thrombocytopenia caused by rifampicin and pyrazinamide // Indian J. Pharmacol. – 2013. – N. 45. – P. 405-407.
23. Chen C., Guo D., Cao X. et al. Risk factors for thrombocytopenia in adult chinese patients receiving linezolid therapy // Curr. Ther. Res. Clin Exp. – 2012. – N. 73. – P. 195–206.
24. Cherylann U.Z., Lawande D., Bagga A.S. Rifampicin induced thrombocytopenia // Ind. J. Tub. – 1995. – Vol. 42. – P. 173.
25. Claps F.X. Two cases of methemoglobinemia and acute hemolytic anemia with death following the ingestion of a solution of paraaminosalicylic acid // Am. Rev. Tuberc. – 1957. – Vol. 76. – N. 5. – P. 862-866.
26. Cormican L.J., Schey S., Milburn H.J. G-CSF enables completion of tuberculosis therapy associated with iatrogenic neutropenia // Eur. Respir. J. – 2004. – N. 23. – P. 649–650.
27. Damasceno G.S., Guaraldo L., Engstrom E.M. et al. Adverse reactions to antituberculosis drugs in Manguinhos, Rio de Janeiro, Brazil // Clinics (Sao Paulo). – 2013. – Vol. 68. – N. 3. – P. 329-337.
28. de Sarachoj O., Zarza L.P., Smucler A. Neutropenia tóxica por fármacos antituberculosos // Arch. Bronconeumol. – 2000. – Vol. 36. – N. 4. – P. 230-231.
29. Díaz-Pollán B., Peña-Pedrosa J.A., Nuñez-Orantos M.J., Sotres-Fernández G. Hemolytic anemia secondary to rifampicin in patient diagnosed of pulmonary tuberculosis reinfection // Rev. Esp. Quimioter. – 2013. – Vol. 26. – N. 4. – P. 369-370.
30. Dixit R., Dixit R., Dixit K. Isoniazid induced pure red cell aplasia // Indian J. Allergy Asthma Immunol. – 2003. – Vol. 17. – N. 2. – P. 93-95.
31. Drug-resistant tuberculosis: a survival guide for clinicians, 2nd ed. - San Francisco, CA: Francis J. Curry National Tuberculosis Center, California Department of Public Health, 2011. – URL: www.currytbcenter.ucsf.edu/drtb. – Accessed 16.06.2014.
32. Fisch P., Handgretinger R., Schaefer H.E. Pure red cell aplasia // Br. J. Haematol. – 2000. – Vol. 111. – N. 4. – P. 1010-1022.
33. Garazzino S., De Rosa F.G., Bargiacchi O. Haematological safety of long-term therapy with linezolid // Int. J. Antimicrob. Agents. – 2007. –Vol. 29. – N. 4. – P. 480-483.
34. George J.N., Raskob G.E., Shah S. et al. Drug induced thrombocytopenia a systematic review of published case reports // Ann. Intern. Med. – 1998. – Vol. 129. – P. 886-890.
35. Gerson S.L, Kaplan S.L, Bruss J.B. et al. Hematologic effects of linezolid: summary of clinical experience // Antimicrob. Agents Chemother. – 2002. – Vol. 46. – P. 2723–2726.
36. Godwin J.E., Braden C.D., Sachdeva K. Neutropenia // eMedicine. 2014. – URL: http://emedicine.medscape.com/article/204821-overview. – Accessed 1/7/2014.
37. Govoni M., Moretti M., Menini C., Fiocchi F. Rifampicin induced immune hemolytic anemia therapeutic relevance of plasma exchange // Vox Sanguinis. – 1990. – Vol. 59. – N. 4. – P. 246-247.
38. Hashiguchi N., Furuyama K., Kim M., Hirose N. A case of pulmonary tuberculosis complicated with severe thrombocytopenia during treatment // Kekkaku. – 2012. – Vol. 87. – N. 4. – P. 345-349.
39. Jaber L., Rigler S., Taya A. et al. A case of isoniazid-induced thrombocytopenia: Recovery with immunoglobulin therapy// Intern. Med. – 2012. – Vol. 51. – P. 745-748.
40. Jenkins P.F., Williams T.D., Campbell I.A. Neutropenia with each standard antituberculosis drug in the same patient // Br. Med. J. – 1980. – Vol. 280. – N. 6221. – P. 1069-1070.
41. Klipstein F.A., Berlinger F.C., Reed L.J. Folate deficiency associated with drug therapy for tuberculosis // Blood. – 1967. – Vol. 29. – N. 5. – P. 697-712.
42. Lee E.J., Lee S.H., Kim Y.E. et al. A case of isoniazid-induced thrombocytopenia: recovery with immunoglobulin therapy // Intern. Med. – 2012. – Vol.51. – N. 7. – P. 745-748.
43. Letona J.M., Barbolla L., Frieyro E. et al. Immune hemolytic anemia and renal failure induced by streptomycin // Br. J. Haematol. – 1977. – Vol. 35. – P. 561-571.
44. Lewis C.R, Manoharan A. Pure red cell hypoplasia secondary to isoniazid // Postgrad. Med. J. – 1987. – Vol. 63. – N. 738. – P. 309-310.
45. Loulergue P., Mir O., Dhote R. Pure red blood cell aplasia and isoniazid use // Emerg. Infect. Dis. – 2007. – Vol. 13. – N. 9. – P. 1427-1428.
46. Mattson K., Jänne J. Mild intravasal haemolysis associated with flu-syndrome during intermittent rifampicin treatment // Eur. J. Respir. Dis. – 1982. – Vol. 63. – N. 1. – P. 68-72.
47. Monson T., Schichman S.A., Zent C.S. Linezolid-induced pure red blood cell aplasia // Clin. Infect. Dis. – 2002. – Vol. 35. – N. 3. – P. 29-31.
48. Mueller-Eckhardt C., Kretschmer V., Coburg K.H. Allergic, immunohemolytic anemia due to para-aminosalicylic acid (PAS): immunohematologic studies of three cases // Dtsch. Med. Wochenschr. – 1972. – Vol. 97. – P. 234-238.
49. Munsiff, S.S., Nilsen, D., Fujiwara, P.I. Tuberculosis: clinical policies and protocols. Bureau of tuberculosis control. – New York City Department of Health and Mental Hygiene, 2008. – URL: http://www.nyc.gov/html/doh/downloads/pdf/tb/tb-protocol.pdf. – Accessed 12.06.2014.
50. Nagayama N., Shishido Y., Masuda K. et al. Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid // Kekkaku. – 2004. – Vol. 79. – N. 5. – P. 341-348.
51. Oðuz A., Kanra T., Gökalp A. et al. Acute hemolytic anemia caused by irregular rifampicin therapy // Turk. J. Pediatr. – 1989. – Vol. 31. – P. 83-88.
52. Oh Y.R., Carr-Lopez S.M., Probasco J.M., Crawley P.G. Levofloxacin-induced autoimmune hemolytic anemia // Ann. Pharmacother. – 2003. – Vol. 37. – N. 7-8. – P. 1010-1003.
53. Ozkalemkas F., Ali R., Ozkan A. et al. Tuberculosis presenting as immune thrombocytopenic purpura // Ann. Clin. Microbiol. Antimicrob. – 2004. – N. 6. – P. 16.
54. Pea F., Viale P, Cojutti P. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients // J. Antimicrob. Chemother. – 2012. – Vol. 67. – N. 8. – P. 2034-2042.
55. Pereira A., Sanz C., Cervantes F., Castillo R. Immune hemolytic anemia and renal failure associated with rifampicin-dependent antibodies with anti-I specificity // Ann Hematol. – 1991. – Vol. 63. – N. 1. – P. 56-58.
56. Review: could Isoniazid cause Aplastic anaemia? // eHealthme; FDA and Social Media, personalized. – 2014. – URL: http://www.ehealthme. com/ds/isoniazid/aplastic+anaemia. – Accessed 03.07.14.
57. Robinson M.G., Foadi M. Hemolytic anemia with positive Coombs’ test: association with isoniazid therapy // JAMA. – 1969. – Vol. 208. – N. 4. – P. 656-658.
58. Song H.H., Lim C.M., Lee S.D. et al. Isolated leukopenia during antituberculosis treatment // Tuberc. Respir. Dis. – 2000. – Vol. 48. – N. 4. – P. 420-427.
59. Soriano A., Ortega M., García S. et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid // Antimicrob. Agents Chemother. – 2007. – N. 51. – P. 2559–2563.
60. Sharp R.A., Lowe J.G., Johnston R.N. Anti-tuberculous drugs and sideroblastic anaemia // Br. J. Clin. Pract. – 1990. –Vol. 44. – P. 706-707.
61. Shishido Y., Nagayama N., Masuda K. et al. Agranulocytosis due to anti-tuberculosis drugs including isoniazid and rifampicin – a report of four cases and review of the literature // Kekkaku. – 2003. – Vol.78. – N. 11. – P. 683-689.
62. Verwilghen R., Reybrouck G., Callens L., Cosemans J. Antituberculous drugs and sideroblastic anaemia // Brit. J. Haematology. – 1965. – Vol. 11. – N. 1. – Р. 92–98.
63. Vives J.F., Rouy J.M., Wagner A., Vallat G. Anemia with hypersideroblastosis during anti-tuberculosis therapy. cure with vitamin therapy // Nouv. Rev. Fr. Hematol. – 1978. – Vol. 20. – P. 99-110.
64. Williams C.K., Aderoju E.A., Adenle A.D. et al. Aplastic anaemia associated with anti-tuberculosis chemotherapy // Acta Haematol. – 1982. – Vol. 68. – N. 4. – P. 329-332.
65. Williamson D.R., Albert M., Heels-Ansdell D. et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes // Chest. – 2013. – Vol. 144. – N. 4. – P. 1207-1215.
66. Yakar F., Yildiz N., Yakar A., Kilıçaslan Z. Isoniazid- and rifampicin-induced thrombocytopenia // Multidiscip. Respir. Med. – 2013. – Vol. 8. – N. 1. – 13.
67. Yeo C.T., Wang Y.T., Poh S.C. Mild haemolysis associated with flu-syndrome during daily rifampicin treatment – a case report // Singapore Med. J. – 1989. – Vol. 30. – N. 2. – P. 215-216.
Review
For citations:
Ivanova D.A. HAEMATOLOGICAL COMPLICATIONS OF ANTI-TUBERCULOSIS CHEMOTHERAPY. Tuberculosis and socially significant diseases. 2014;(4):56-65. (In Russ.)
Views:
31
Email this article 